title: Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study.
abstract: Immediate reocclusion after successful thrombolysis was angiographically examined in 29 consecutive stroke patients. The reocclusion, which was associated with a high-grade residual stenosis of initially perfused arteries, occurred in four patients. IV abciximab successfully dissolved the thrombus in all four patients. Rapid thrombotic reocclusion after successful thrombolysis is commonly observed in patients after an acute stroke. Administration of abciximab may lead to reperfusion of the reoccluded artery.
authors.affiliation: Department of Neurology, Yonsei University College of Medicine, Brain Korea 21 Project, Seoul, Korea. jhheo@yumc.yonsei.ac.kr
authors.forename: Ji Hoe
authors.initials: JH
authors.lastname: Heo
authors.forename: Kyung Yul
authors.initials: KY
authors.lastname: Lee
authors.forename: Seo Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Dong Ik
authors.initials: DI
authors.lastname: Kim
mesh_terms: D000077284:Abciximab; D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology*; D002533:Cerebral Angiography; D002536:Cerebral Arteries / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D003251:Constriction, Pathologic; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D012008:Recurrence; D015424:Reperfusion; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D017211:Treatment Failure; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014654:Vascular Patency
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab